Re: Human Papillomavirus DNA and p53 Polymorphisms in Squamous Cell Carcinomas From Fanconi Anemia Patients

Kutler et al. (1) recently reported that human papillomavirus (HPV) DNA is frequently detected in squamous cell carcinomas (SCCs) of Fanconi anemia patients, who are predisposed to develop cancer at an early age, particularly acute myeloid leukemia and SCCs of the head and neck (HNSCCs) and the anogenital region. Kutler et al. speculated that HPV infection might be critically involved in the pathogenesis of SCC in Fanconi anemia patients, which raises hope that vaccination against HPV might prevent such tumors. HPV is known to be etiologically involved in SCCs that arise in the anogenital region (cervix) and in a minority of HNSCCs, particularly those in the oropharynx (2,3). Inhibitory oncoproteins expressed by HPV cause inactivation of the p53 and pRb pathways. HNSCCs that contain transcriptionally active HPV DNA typically lack mutations in TP53, the gene encoding p53, whereas 50%–60% of HNSCCs that do not contain HPV DNA have mutations in TP53 (2).

Kutler et al. (1) report that 15 of the 18 HNSCCs (all in the oral cavity) from the Fanconi anemia patients in their study had detectable HPV DNA and that none of the 18 HNSCCs contained a mutation in TP53, HPV DNA was detected by polymerase chain reaction (PCR) in laser-microdissected tissue, and quantitative PCR was used to determine HPV DNA; this method can detect as few as one copy of HPV16 DNA per 5000 cells (4). However, none of the HNSCC specimens from the Fanconi anemia patients we tested were positive for HPV DNA, which made further quantitative analysis redundant. Results of previous studies suggest that the likely involvement of HPV in the etiology of a tumor is reflected by the presence of at least one copy of HPV DNA in every cancer cell (2,5). To obtain independent confirmation of the HPV DNA status of HNSCCs from Fanconi anemia patients, we suggest that loss-of-heterozygosity patterns in the tumor DNA could be evaluated, because we have found that HNSCCs with transcriptionally active HPV DNA appear to exhibit a loss-of-heterozygosity pattern that is strikingly different from that observed among HNSCCs without detectable HPV DNA (6).

Until these issues have been examined in more detail, we wish to caution against raising too much hope that HPV vaccination (7) will be an option to prevent HNSCC in Fanconi anemia patients. The current policy of frequent surveillance and examination of biopsy samples of suspected tissues in the oral cavity and oropharynx should remain part of the standard practice in the clinical management of Fanconi anemia patients, including those who are enrolled in preventive vaccination trials.

Hester J. T. van Zeeburg
Peter J. F. Snijders

REFERENCES


NOTES

Affiliations of authors: Department of Otolaryngology/Head-Neck Surgery (HTVZ, RHB), Department of Pathology (PHS), and Department of Clinical Genetics and Human Genetics (HJ), Vrije Universiteit Medical Center, Amsterdam, the Netherlands.

Correspondence to: R. H. Brakenhoff, PhD, Tumor Biology Section, Department of Otolaryngology/Head-Neck Surgery, Vrije Universiteit Medical Center, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands (e-mail: rh.brakenhoff@vumc.nl). DOX: 10.1093/jnci/djh178

RESPONSE

We reported a high prevalence of human papillomavirus (HPV) DNA and the absence of p53 mutations among 24 squamous cell carcinomas (SCCs) from 25 Fanconi anemia patients (1). By con-
trast, van Zeeburg et al. describe an unpublished series of five cases of head and neck squamous cell carcinoma (HNSCC) from Fanconi anemia patients in which they identified mutations in p53 in four cases and the absence of detectable HPV DNA in all cases.

Several factors may explain the different results obtained in these two studies, the least persuasive of which are the small sample size in the van Zeeberg et al. study and methodologic differences between the studies, including the source of DNA (we used laser capture microdissected specimens), the oligonucleotide primers used for HPV DNA detection (we used highly efficient CPI and CPIIG consensus primers and validated all findings with real-time polymerase chain reaction), and stringency of analyses performed (our experiments were repeated at least three times) (2,3).

One of the more important reasons for the differing results may be case selection. We included all cases of SCC reported in the International Fanconi Anemia Registry (IFAR) without restrictions. Conversely, the cases van Zeeburg et al. report on were presumably selected on the basis of the authors’ ability to establish long-term tumor cell cultures (at least for four of the five reported cases). This is an important distinction, because SCCs from Fanconi anemia patients are known to be difficult to put into culture, and therefore the cases reported by van Zeeburg et al. may not be representative of the HNSCCs found in Fanconi anemia patients.

A major clinical difference between SCCs in Fanconi anemia patients and those in the general population is the lower prevalence of tobacco and/or alcohol use among Fanconi anemia patients, which is known to have a substantial impact on the pattern of genomic aberrations in SCCs (4). Although van Zeeburg et al. agree that this is an important issue, they do not provide the carcinogen exposure histories for their case patients. Interestingly, one of the authors has previously published data on the absence of detectable HPV DNA in two of the five cases included in the current series (5). In that study, both cases of HNSCC occurred in patients who had a clinically significant history of tobacco or alcohol exposure, which sharply contrasts with the tobacco and/or alcohol exposures of most Fanconi anemia patients who develop SCC (5).

Our unpublished observations suggest that the incidence, pathogenesis, and genomic composition of Fanconi anemia-associated HNSCC that develop in patients who suffer graft-versus-host disease after having a bone marrow transplant may be different from those occurring in the absence of this disease (Kutler DI, Wreesmann VB, Goberdhan A, Ben-Porat L, Satagopan J, Ngai I, et al.: unpublished observations). In this respect, it is interesting to note that the rate of graft-versus-host disease is historically higher in Europe than in the United States due to differences in transplantation protocols. This clinical information should also be provided by van Zeeburg et al. to allow a meaningful assessment of their results.

Finally, on the basis of their unpublished findings, van Zeeburg et al. suggest that a unique pattern of loss-of-heterozygosity may help identify HPV DNA-positive HNSCCs. However, there are several problems with this approach. Fewer than 10% of patients with HNSCC in the general population report having no history of tobacco or alcohol use. Accordingly, the substantial amount of tobacco and/or alcohol consumption has complicated delineation of the contributions of HPV to the pathogenesis of HNSCC in the general population, not to mention the identification of reproducible differences in the genetic composition in HPV-related and HPV-unrelated cases of HNSCC. We performed a genomic screening study comparing all cases of HNSCC in Fanconi anemia patients (N = 18) with a group of randomly selected cases of HNSCC from the general population (n = 42; Kutler DI, Wreesmann VB, Goberdhan A, Ben-Porat L, Satagopan J, Ngai I, et al.: unpublished data). We found statistically significant differences in the pattern and frequency of chromosomal aberrations detected by comparative genomic hybridization between HNSCCs from the two populations. This result differs considerably from that in a previous report on two of the five cases in the authors’ series, in which no differences in chromosomal aberrations were found between the HNSCCs in two Fanconi anemia patients and those in the general population, reflecting the selection bias for the cases in their series (5).

Overall, the high prevalence of HNSCC in Fanconi anemia patients re-quires diligent surveillance of this patient population. On the basis of our findings, the role of HPV in the pathogenesis of HNSCC in Fanconi anemia patients merits further investigation, as does HPV vaccination as a mode of cancer prevention.

References


Notes

Affiliation of authors: Laboratory of Epithelial Cancer Biology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Correspondence to: Bhuvanesh Singh, MD, Laboratory of Epithelial Cancer Biology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021 (e-mail: singbh@mskcc.org).

DOI: 10.1093/jnci/djh179